Trastuzumab Emtansine
- TRADE NAME: Kadcyla (Genentech)
- INDICATIONS: HER2-positive, metastatic breast cancer in patients who previously received trastuzumab and a taxane, separately or in combination
- SYNONYM: T-DM1
- CLASS: Antibody drug conjugate (ADC), Biologic, HER2-targeted antibody-drug conjugate, Monoclonal antibody
- HALF-LIFE: 4 days
FDA APPROVAL DATE: 07/11/2014
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:None known
PREGNANCY CATEGORY: D
HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY
See full prescribing information for complete boxed warning.
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric